Tecan Group AG (SWX:TECN)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 1.48B |
| Revenue (ttm) | 882.48M |
| Net Income (ttm) | -110.65M |
| Shares Out | 12.53M |
| EPS (ttm) | -8.74 |
| PE Ratio | n/a |
| Forward PE | 18.71 |
| Dividend | 3.00 (2.52%) |
| Ex-Dividend Date | Apr 17, 2026 |
| Volume | 82,999 |
| Average Volume | 50,980 |
| Open | 118.20 |
| Previous Close | 119.10 |
| Day's Range | 116.80 - 119.80 |
| 52-Week Range | 110.60 - 177.50 |
| Beta | 1.11 |
| RSI | 34.06 |
| Earnings Date | Aug 11, 2026 |
About Tecan Group AG
Tecan Group AG provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally. It operates in two segments: Life Sciences Business and Partnering Business. The company offers liquid handling and automation, microplate readers and washers, software, consumables, sequencing reagents, immunoassays and antibodies, and Tecan Labwerx, an end-to-end automation solution. It also provides PARAMIT, a contract design and manufacturing service. Tecan Group AG has ... [Read more]
Financial Performance
Financial StatementsNews
Tecan Appoints Camila Japur As CFO
(RTTNews) - Tecan Group AG (TCHBF, TCGGY, TECN.SW), a Swiss company providing laboratory instruments and solutions, on Monday announced the appointment of Camila Japur as Chief Financial Officer, effe...
Tecan Group AG Earnings Call Transcript: H2 2025
2025 saw a slight sales decline and a net loss due to impairment, but strong cash flow and a robust order book. The Rewire program targets CHF 1 billion sales and 20% EBITDA by 2028, with gradual market recovery and operational improvements expected.
Tecan Group AG Transcript: 44th Annual J.P. Morgan Healthcare Conference
A new CEO is driving a transformation program focused on portfolio discipline, commercial and operational excellence to reignite growth. Automation and AI are key market drivers, with new products and geographic expansion supporting a gradual recovery and midterm growth targets.
Q3 2025 Qualitative Update: Tecan reports mid-single-digit local currency growth in the third quarter and confirms full-year 2025 outlook
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Q3 2025 Qualitative Update: Tecan reports mid-single-digit local currency growth in the third quarter and confir...
Tecan Group AG Earnings Call Transcript: H1 2025
Revenue and adjusted EBITDA for H1 2025 met expectations amid challenging markets, with strong clinical diagnostics and improved gross margin offsetting declines in China and Partnering. Full-year guidance is maintained, with tariff and FX risks mitigated by cost controls and operational flexibility.
Tecan Group AG Earnings Call Transcript: H2 2024
2024 saw double-digit sales and profit declines due to weak biopharma, US government, and China demand, but recurring revenues and clinical diagnostics offset some headwinds. 2025 guidance anticipates flat to slightly positive sales, with margin improvement from cost savings and new product launches.
Tecan Group AG Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025
The conference highlighted a resilient, innovation-driven strategy focused on automation, digital solutions, and high-growth applications in genomics and proteomics. Despite a challenging 2024, with revenue declines in China and biopharma, the company reaffirmed its midterm growth and margin outlook, supported by ongoing M&A and sustainability initiatives.
Tecan Group AG Transcript: CMD 2024
Facing a challenging 2024 with revised guidance due to OEM demand deferrals and China softness, the company is implementing cost controls and focusing on high-growth segments, digital innovation, and global expansion. Mid-term, it targets a return to above-market growth and margin improvement, supported by strong recurring revenue and new product launches like Veya.
Tecan Group AG Earnings Call Transcript: H1 2024
Sales declined 11.6% in local currencies in H1 2024, mainly due to biopharma and China weakness, with adjusted EBITDA margin at 14.5%. Guidance for 2024 was revised downward, but order intake improved in Q2 and new product launches are expected to drive growth in 2025.